We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
(-22%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-9.32%
Top 10 Holdings %
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$31.2M |
| 2 |
Organon & Co
OGN
|
+$23M |
| 3 |
Community Health Systems
CYH
|
+$19.2M |
| 4 |
R1 RCM Inc. Common Stock
RCM
|
+$18.6M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$17.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$71.3M |
| 2 |
GSK
GSK
|
+$28.4M |
| 3 |
TG Therapeutics
TGTX
|
+$27.2M |
| 4 |
Elevance Health
ELV
|
+$20.5M |
| 5 |
CATALENT, INC.
CTLT
|
+$17.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.27% |
| 2 | Miscellaneous | 33.54% |
| 3 | Industrials | 1.14% |
| 4 | Financials | 0.05% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Ionis Pharmaceuticals
IONS
$7.33B
| $17.6M | 1.18% |
+442,000
| New | +$17.3M |
2021 Q2
0 quarters
|
|
|
27
DELISTED
R1 RCM Inc. Common Stock
RCM
| $17.1M | 1.14% |
+770,000
| New | +$18.6M |
2021 Q2
0 quarters
|
|
28
HealthEquity
HQY
$7.65B
| $15.9M | 1.06% |
+197,500
| New | +$15M |
2021 Q2
0 quarters
|
|
29
AMN Healthcare
AMN
$1.55B
| $15.4M | 1.03% |
+159,101
| New | +$13.8M |
2021 Q2
0 quarters
|
|
30
Omnicell
OMCL
$1.64B
| $14.9M | 0.99% |
+98,366
| New | +$13.7M |
2021 Q2
0 quarters
|
|
31
McKesson
MCK
$116B
| $14.4M | 0.96% |
75,000
-47,983
| -39% | -$9.27M |
2021 Q1
1 quarter
|
|
32
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.9B
| $13.5M | 0.9% |
+100,000
| New | +$13.1M |
2021 Q2
0 quarters
|
|
33
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $12.5M | 0.84% |
174,249
+9,871
| +6% | +$725K |
2019 Q4
6 quarters
|
|
34
ARK Innovation ETF
ARKK
$8.92B
| $11.1M | 0.74% |
85,000
+3,000
| +4% | +$350K |
2021 Q1
1 quarter
|
|
35
Vertex Pharmaceuticals
VRTX
$129B
| $11M | 0.73% |
+54,500
| New | +$11.4M |
2021 Q2
0 quarters
|
|
36
Cigna
CI
$79B
| $9.9M | 0.66% |
41,745
+1,745
| +4% | +$436K |
2021 Q1
1 quarter
|
|
|
MGLN
37
DELISTED
Magellan Health Services, Inc.
MGLN
| $9.86M | 0.66% |
104,700
| – | – |
2020 Q4
2 quarters
|
|
38
PUT
iShares TIPS Bond ETF
TIP
$14.4B
| $8.96M | 0.6% |
+70,000
| New | +$8.89M |
2021 Q2
0 quarters
|
|
39
Alnylam Pharmaceuticals
ALNY
$31.3B
| $8.67M | 0.58% |
51,136
-29,801
| -37% | -$4.36M |
2021 Q1
1 quarter
|
|
|
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
| $8.57M | 0.57% |
495,860
-327,369
| -40% | -$6.02M |
2017 Q4
14 quarters
|
|
41
Humana
HUM
$51.9B
| $8.27M | 0.55% |
18,656
-6,183
| -25% | -$2.7M |
2021 Q1
1 quarter
|
|
42
CALL
Teladoc Health
TDOC
$1.08B
| $6.65M | 0.44% |
+40,000
| New | +$6.48M |
2021 Q2
0 quarters
|
|
|
HZNP
43
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.55M | 0.44% |
+70,000
| New | +$6.44M |
2021 Q2
0 quarters
|
|
44
Option Care Health
OPCH
$4.68B
| $6.33M | 0.42% |
+289,297
| New | +$5.58M |
2021 Q2
0 quarters
|
|
45
Outset Medical
OM
$76.7M
| $5.36M | 0.36% |
+7,153
| New | +$5.47M |
2021 Q2
0 quarters
|
|
46
Centene
CNC
$34.8B
| $4.96M | 0.33% |
68,000
-23,120
| -25% | -$1.58M |
2021 Q1
1 quarter
|
|
|
SRGA
47
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $4.91M | 0.33% |
129,403
+41,410
| +47% | +$2.12M |
2021 Q1
1 quarter
|
|
48
DELISTED
Affimed
AFMD
| $4.82M | 0.32% |
56,694
-47,919
| -46% | -$4.37M |
2018 Q1
13 quarters
|
|
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.79M | 0.32% |
117,462
-183,125
| -61% | -$6.77M |
2020 Q3
3 quarters
|
|
|
50
GSK
GSK
$98.2B
| $4.61M | 0.31% |
90,143
-591,622
| -87% | -$28.4M |
2018 Q1
13 quarters
|
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q2 2021 Portfolio in Review
As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.
- Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
- Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
- Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
- Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
- Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
- Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
- Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.
Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.